Adicet Bio (ACET) News Today $0.97 -0.06 (-5.84%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Adicet Bio begins lupus nephritis trial, eyes other diseasesNovember 20 at 11:50 PM | uk.investing.comAdicet Bio begins trial for innovative cancer therapyNovember 20 at 11:50 PM | investing.comAdicet Bio opens enrollment for ADI-270 phase 1 clinical trial in ccRCCNovember 19 at 1:13 AM | markets.businessinsider.comAdicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell CarcinomaNovember 18 at 8:11 PM | finance.yahoo.comAdicet Bio:1st patient dosed in trial evaluating ADI-001 in autoimmune diseasesNovember 18 at 8:11 PM | markets.businessinsider.comAdicet Bio (NASDAQ:ACET) Receives Neutral Rating from HC WainwrightHC Wainwright restated a "neutral" rating on shares of Adicet Bio in a research report on Monday.November 18 at 12:42 PM | marketbeat.comAdicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024November 16, 2024 | businesswire.comAdicet Bio IncNovember 15, 2024 | money.usnews.comAnalysts Issue Forecasts for Adicet Bio FY2024 EarningsNovember 12, 2024 | americanbankingnews.comHC Wainwright Decreases Earnings Estimates for Adicet BioAdicet Bio, Inc. (NASDAQ:ACET - Free Report) - HC Wainwright decreased their FY2024 EPS estimates for shares of Adicet Bio in a research note issued to investors on Thursday, November 7th. HC Wainwright analyst E. White now forecasts that the company will earn ($1.39) per share for the year, downNovember 11, 2024 | marketbeat.comAdicet Bio (NASDAQ:ACET) Rating Lowered to "Sell" at StockNews.comNovember 11, 2024 | americanbankingnews.comAdicet Bio: Hold Rating Amid Financial Stability and Anticipated Clinical DataNovember 8, 2024 | markets.businessinsider.comH.C. Wainwright Sticks to Its Hold Rating for Adicet Bio (ACET)November 8, 2024 | markets.businessinsider.comAdicet Bio (NASDAQ:ACET) Announces Earnings Results, Hits EstimatesAdicet Bio (NASDAQ:ACET - Get Free Report) released its earnings results on Wednesday. The company reported ($0.34) EPS for the quarter, meeting analysts' consensus estimates of ($0.34).November 7, 2024 | marketbeat.comAdicet Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 6, 2024 | businesswire.comAdicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024November 6, 2024 | uk.finance.yahoo.comAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)October 31, 2024 | businesswire.comAdicet Bio Advances FDA-Approved Autoimmune Therapy TrialsOctober 17, 2024 | finance.yahoo.comH.C. Wainwright Reaffirms Their Hold Rating on Adicet Bio (ACET)October 17, 2024 | markets.businessinsider.comAdicet Bio (NASDAQ:ACET) Given Neutral Rating at HC WainwrightHC Wainwright reissued a "neutral" rating on shares of Adicet Bio in a research report on Wednesday.October 16, 2024 | marketbeat.comAdicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person SyndromeOctober 16, 2024 | finance.yahoo.comAdicet Bio, Inc. (NASDAQ:ACET) Sees Large Decline in Short InterestAdicet Bio, Inc. (NASDAQ:ACET - Get Free Report) saw a large decline in short interest in September. As of September 30th, there was short interest totalling 3,720,000 shares, a decline of 11.0% from the September 15th total of 4,180,000 shares. Based on an average daily volume of 676,900 shares, the short-interest ratio is presently 5.5 days.October 15, 2024 | marketbeat.comCubist Systematic Strategies LLC Boosts Holdings in Adicet Bio, Inc. (NASDAQ:ACET)Cubist Systematic Strategies LLC increased its holdings in Adicet Bio, Inc. (NASDAQ:ACET - Free Report) by 790.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 409,049 shares of the coOctober 13, 2024 | marketbeat.comMillennium Management LLC Adjusts Stake in Adicet Bio IncOctober 10, 2024 | finance.yahoo.comAdicet Bio (NASDAQ:ACET) Raised to "Hold" at StockNews.comStockNews.com upgraded shares of Adicet Bio from a "sell" rating to a "hold" rating in a research note on Tuesday.October 8, 2024 | marketbeat.comAdicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC raised its holdings in Adicet Bio, Inc. (NASDAQ:ACET - Free Report) by 790.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 409,049 shares of the company's stock after buying an additional 363,095 shares dOctober 5, 2024 | marketbeat.comRenaissance Technologies LLC Has $1.83 Million Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET)Renaissance Technologies LLC increased its holdings in shares of Adicet Bio, Inc. (NASDAQ:ACET - Free Report) by 44.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,512,600 shares of the company's stock after acquiriOctober 4, 2024 | marketbeat.comStonepine Capital Management LLC Has $737,000 Holdings in Adicet Bio, Inc. (NASDAQ:ACET)Stonepine Capital Management LLC lifted its stake in Adicet Bio, Inc. (NASDAQ:ACET - Free Report) by 330.6% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 609,446 shares of the company's stock after purchasing an additioOctober 1, 2024 | marketbeat.comAdicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer ConferenceSeptember 30, 2024 | finance.yahoo.comAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 30, 2024 | businesswire.comHC Wainwright Reiterates Neutral Rating for Adicet Bio (NASDAQ:ACET)HC Wainwright reiterated a "neutral" rating on shares of Adicet Bio in a research note on Monday.September 30, 2024 | marketbeat.comAdicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune DiseasesSeptember 30, 2024 | finance.yahoo.comGuggenheim Begins Coverage on Adicet Bio (NASDAQ:ACET)Guggenheim began coverage on shares of Adicet Bio in a research report on Monday. They issued a "buy" rating and a $7.00 price target for the company.September 30, 2024 | marketbeat.comTruist Financial Sticks to Their Buy Rating for Adicet Bio (ACET)September 28, 2024 | markets.businessinsider.comAdicet Bio’s ADI-001 Shows Promising Efficacy in B-cell Malignancies: Maintaining Buy Rating with a $8 Price TargetSeptember 20, 2024 | markets.businessinsider.comTruist Financial Issues a Buy Rating on Adicet Bio (ACET)September 20, 2024 | markets.businessinsider.comAdicet Bio (NASDAQ:ACET) Rating Reiterated by WedbushWedbush reaffirmed an "outperform" rating and issued a $5.00 price objective on shares of Adicet Bio in a research report on Friday.September 20, 2024 | marketbeat.comBuy Rating on Adicet Bio: Promising Phase 1 GLEAN Study Results and Therapeutic Potential in NHLSeptember 20, 2024 | markets.businessinsider.comAdicet Bio: Phase 1 GLEAN Trial Reinforces Potential Of ADI-001 - Quick FactsSeptember 19, 2024 | markets.businessinsider.comADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid TissueSeptember 19, 2024 | businesswire.comAdicet Bio, Inc. (NASDAQ:ACET) Shares Purchased by Acadian Asset Management LLCAcadian Asset Management LLC increased its position in shares of Adicet Bio, Inc. (NASDAQ:ACET - Free Report) by 205.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,085,093 shares of tSeptember 16, 2024 | marketbeat.comEquities Analysts Offer Predictions for Adicet Bio, Inc.'s FY2026 Earnings (NASDAQ:ACET)Adicet Bio, Inc. (NASDAQ:ACET - Free Report) - Investment analysts at Wedbush issued their FY2026 earnings per share (EPS) estimates for shares of Adicet Bio in a report released on Tuesday, September 10th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($1.11) per sSeptember 13, 2024 | marketbeat.comAdicet Bio (ACET) was downgraded to a Hold Rating at H.C. WainwrightSeptember 12, 2024 | markets.businessinsider.comBuy Rating for Adicet Bio Backed by Strong Cell Therapy Potential and Upcoming Data ReleasesSeptember 11, 2024 | markets.businessinsider.comHC Wainwright & Co. Downgrades Adicet Bio (ACET)September 11, 2024 | msn.comAdicet Bio narrows focus on lead asset (update)September 11, 2024 | msn.comCanaccord Genuity Group Cuts Adicet Bio (NASDAQ:ACET) Price Target to $8.00Canaccord Genuity Group decreased their price target on shares of Adicet Bio from $19.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday.September 11, 2024 | marketbeat.comAdicet Bio (NASDAQ:ACET) Downgraded to "Neutral" at HC WainwrightHC Wainwright cut shares of Adicet Bio from a "buy" rating to a "neutral" rating in a research note on Wednesday.September 11, 2024 | marketbeat.comStockNews.com Downgrades Adicet Bio (NASDAQ:ACET) to SellStockNews.com lowered shares of Adicet Bio from a "hold" rating to a "sell" rating in a report on Tuesday.September 10, 2024 | marketbeat.comStockNews.com Upgrades Adicet Bio (NASDAQ:ACET) to "Hold"StockNews.com raised shares of Adicet Bio from a "sell" rating to a "hold" rating in a research note on Friday.August 30, 2024 | marketbeat.com Get Adicet Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ACET and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin ACET Media Mentions By Week ACET Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACET News Sentiment▼0.040.45▲Average Medical News Sentiment ACET News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACET Articles This Week▼92▲ACET Articles Average Week Get Adicet Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ACET and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TITN News GWW News URI News FAST News WSO News AIT News WCC News BECN News GATX News AL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACET) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adicet Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adicet Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACET Stock Alerts